OTCPK:ABSC.F

Stock Analysis Report

Executive Summary

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has AB Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABSC.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

29.1%

ABSC.F

-0.5%

US Pharmaceuticals

-1.1%

US Market


1 Year Return

n/a

ABSC.F

6.3%

US Pharmaceuticals

17.8%

US Market

Return vs Industry: Insufficient data to determine how ABSC.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ABSC.F performed against the US Market.


Shareholder returns

ABSC.FIndustryMarket
7 Day29.1%-0.5%-1.1%
30 Day81.1%-1.0%1.5%
90 Dayn/a5.8%6.6%
1 Yearn/a8.8%6.3%20.2%17.8%
3 Yearn/a25.4%16.6%47.5%38.1%
5 Year-43.7%-43.7%29.0%15.1%71.2%52.4%

Price Volatility Vs. Market

How volatile is AB Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AB Science undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether AB Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AB Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ABSC.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AB Science regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is AB Science forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-9.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ABSC.F's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if ABSC.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ABSC.F's revenue is expected to decline over the next 3 years (-9.3% per year).

High Growth Revenue: ABSC.F's revenue is forecast to decline over the next 3 years (-9.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABSC.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AB Science performed over the past 5 years?

-7.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABSC.F is currently unprofitable.

Growing Profit Margin: ABSC.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABSC.F is unprofitable, and losses have increased over the past 5 years at a rate of -7.8% per year.

Accelerating Growth: Unable to compare ABSC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABSC.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).


Return on Equity

High ROE: ABSC.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AB Science's financial position?


Financial Position Analysis

Short Term Liabilities: ABSC.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ABSC.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ABSC.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ABSC.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ABSC.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: ABSC.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABSC.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ABSC.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.8% each year


Next Steps

Dividend

What is AB Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ABSC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABSC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABSC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABSC.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABSC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average board tenure


CEO

Alain Moussy 0

18.6yrs

Tenure

€482,000

Compensation

Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001. Mr. Moussy has been Scientific Director at AB Science S.A. since January 2004. He serves a ...


CEO Compensation Analysis

Compensation vs Market: Alain's total compensation ($USD523.57K) is below average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Alain's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Alain Moussy
Co-Founder18.6yrs€482.00k2.85% 12.9m
Jean-Pierre Kinet
Director18.6yrsno datano data
Patrick Moussy
Director18.6yrsno datano data
Brigitte Reverdin
Independent Director4.5yrsno datano data
Nathalie Riez
Director2.2yrsno datano data
Emmanuelle Mourey
Independent Director1.7yrsno datano data
Béatrice Bihr
1.7yrsno datano data

4.5yrs

Average Tenure

Experienced Board: ABSC.F's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.4%.


Top Shareholders

Company Information

AB Science S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AB Science S.A.
  • Ticker: ABSC.F
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €416.370m
  • Listing Market Cap: €452.281m
  • Shares outstanding: 44.06m
  • Website: https://www.ab-science.com

Number of Employees


Location

  • AB Science S.A.
  • 3, Avenue George V
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABENXTPA (Euronext Paris)YesCommon SharesFREURApr 2010
A8DDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2010
0Q77LSE (London Stock Exchange)YesCommon SharesGBEURApr 2010
ABSC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2010
ABPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURApr 2010

Biography

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the Masitinib, a tyrosine kinase inhibitor that is in Phase III trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939 for the treatment of acute myeloid leukemia. The company markets its Masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:33
End of Day Share Price2020/02/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.